Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077016887> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2077016887 endingPage "S44" @default.
- W2077016887 startingPage "S44" @default.
- W2077016887 abstract "The long-term tolerability and effectiveness of oxymorphone extended release (ER) were evaluated in an open-label study in opioid-naive outpatients (≥18 years of age) with moderate to severe chronic noncancer pain. Patients received oxymorphone ER at 5 mg q12h and were titrated to a dose that reduced average pain to °Ü 4 on the 0¨ C10 Brief Pain Inventory scale (BPI question 5). Titration-phase results were presented previously, with 94 of 126 patients (75%) achieving an effective stable daily dose 1Hale M et al., American Pain Society 23rd Annual Scientific Meeting, 2004. Follow-up data are now reported on 94 patients who entered a 5-month maintenance period. Sixty patients (63.8%) completed the maintenance period, with additional dosage adjustments and use of rescue medication (oxymorphone immediate release [IR] 5 mg) as needed. From baseline to study end, mean average pain intensity decreased from 6.2 to 2.2 on the 11-point BPI scale (P<0.001). From the beginning of the maintenance phase (days 1¨ C30) to the end (days 121¨ C150), the average daily dose of oxymorphone ER ranged from a mean of 27.8 to 30.8 mg. For the 68.1% of patients who used oxymorphone IR rescue medication, the mean daily average dose ranged from 6.1¨ C7.6 mg. The most common adverse events (AEs) were constipation (17.0%), nausea (9.6%), nasopharyngitis (8.5%), somnolence (6.4%), and dizziness (6.4%). Most AEs were mild to moderate in severity. Fifteen patients (16%) discontinued because of AEs considered possibly or probably related to oxymorphone ER. Oxymorphone ER was well tolerated in opioid-naive patients over a 6-month period when therapy was initiated at a low dose (5 mg q12h), followed by titration to a stable dose that provided effective relief for moderate to severe pain. Support was provided by Endo Pharmaceuticals, Inc. and Penwest Pharmaceutical Co. 1Hale M et al., American Pain Society 23rd Annual Scientific Meeting, 2004" @default.
- W2077016887 created "2016-06-24" @default.
- W2077016887 creator A5010550037 @default.
- W2077016887 creator A5018225204 @default.
- W2077016887 creator A5025923923 @default.
- W2077016887 creator A5068633044 @default.
- W2077016887 creator A5080259911 @default.
- W2077016887 creator A5089708517 @default.
- W2077016887 date "2005-03-01" @default.
- W2077016887 modified "2023-09-26" @default.
- W2077016887 title "Effective long-term management of opioid-naive patients with oxymorphone extended release" @default.
- W2077016887 doi "https://doi.org/10.1016/j.jpain.2005.01.171" @default.
- W2077016887 hasPublicationYear "2005" @default.
- W2077016887 type Work @default.
- W2077016887 sameAs 2077016887 @default.
- W2077016887 citedByCount "1" @default.
- W2077016887 crossrefType "journal-article" @default.
- W2077016887 hasAuthorship W2077016887A5010550037 @default.
- W2077016887 hasAuthorship W2077016887A5018225204 @default.
- W2077016887 hasAuthorship W2077016887A5025923923 @default.
- W2077016887 hasAuthorship W2077016887A5068633044 @default.
- W2077016887 hasAuthorship W2077016887A5080259911 @default.
- W2077016887 hasAuthorship W2077016887A5089708517 @default.
- W2077016887 hasBestOaLocation W20770168871 @default.
- W2077016887 hasConcept C126322002 @default.
- W2077016887 hasConcept C170493617 @default.
- W2077016887 hasConcept C197934379 @default.
- W2077016887 hasConcept C2776029756 @default.
- W2077016887 hasConcept C2776316548 @default.
- W2077016887 hasConcept C2778375690 @default.
- W2077016887 hasConcept C2779034229 @default.
- W2077016887 hasConcept C2780580376 @default.
- W2077016887 hasConcept C2781063702 @default.
- W2077016887 hasConcept C2781112942 @default.
- W2077016887 hasConcept C2781440901 @default.
- W2077016887 hasConcept C3020385749 @default.
- W2077016887 hasConcept C42219234 @default.
- W2077016887 hasConcept C71924100 @default.
- W2077016887 hasConcept C98274493 @default.
- W2077016887 hasConceptScore W2077016887C126322002 @default.
- W2077016887 hasConceptScore W2077016887C170493617 @default.
- W2077016887 hasConceptScore W2077016887C197934379 @default.
- W2077016887 hasConceptScore W2077016887C2776029756 @default.
- W2077016887 hasConceptScore W2077016887C2776316548 @default.
- W2077016887 hasConceptScore W2077016887C2778375690 @default.
- W2077016887 hasConceptScore W2077016887C2779034229 @default.
- W2077016887 hasConceptScore W2077016887C2780580376 @default.
- W2077016887 hasConceptScore W2077016887C2781063702 @default.
- W2077016887 hasConceptScore W2077016887C2781112942 @default.
- W2077016887 hasConceptScore W2077016887C2781440901 @default.
- W2077016887 hasConceptScore W2077016887C3020385749 @default.
- W2077016887 hasConceptScore W2077016887C42219234 @default.
- W2077016887 hasConceptScore W2077016887C71924100 @default.
- W2077016887 hasConceptScore W2077016887C98274493 @default.
- W2077016887 hasIssue "3" @default.
- W2077016887 hasLocation W20770168871 @default.
- W2077016887 hasOpenAccess W2077016887 @default.
- W2077016887 hasPrimaryLocation W20770168871 @default.
- W2077016887 hasRelatedWork W1973342136 @default.
- W2077016887 hasRelatedWork W2002502340 @default.
- W2077016887 hasRelatedWork W2022556905 @default.
- W2077016887 hasRelatedWork W2157361622 @default.
- W2077016887 hasRelatedWork W2371615325 @default.
- W2077016887 hasRelatedWork W2393784267 @default.
- W2077016887 hasRelatedWork W2394317912 @default.
- W2077016887 hasRelatedWork W3031282144 @default.
- W2077016887 hasRelatedWork W3211205717 @default.
- W2077016887 hasRelatedWork W4251165208 @default.
- W2077016887 hasVolume "6" @default.
- W2077016887 isParatext "false" @default.
- W2077016887 isRetracted "false" @default.
- W2077016887 magId "2077016887" @default.
- W2077016887 workType "article" @default.